myeloma panel compares real-world versus clinical trial data for car-ts, bispecifics
Published 10 months ago • 425 plays • Length 6:17Download video MP4
Download video MP3
Similar videos
-
6:47
myeloma panel discusses the latest car-t treatment data
-
8:14
bispecific versus car t-cell therapy for myeloma and bridging therapy needs for car-t
-
49:59
car t-cell therapy: multiple myeloma
-
8:00
treatment selection for relapsed multiple myeloma: car-t versus bispecifics
-
6:47
toxicity management: car-ts versus bispecific t-cell engagers
-
5:19
bcma-targeted car-ts and their role in late-relapse multiple myeloma
-
5:05
myeloma treatment selection: car-t versus bispecific t-cell engagers, bridging therapy options
-
59:53
clinical trials in multiple myeloma
-
9:13
panel discusses use of bispecifics to treat relapsed/refractory myeloma, toxicity considerations
-
1:14
clinical benefit of teclistamab vs real-world physician’s choice for r/r multiple myeloma
-
6:38
comparison of the safety & efficacy of car-t therapy vs bispecifics in r/r multiple myeloma
-
0:39
car-t, bispecifics and mrd: how is treatment for multiple myeloma evolving?
-
8:56
myeloma research | car-t cell & bispecifics study updates
-
2:27
addressing the disparity in ethnic variation in uk-based clinical trials for multiple myeloma
-
3:05
updates from the determination trial: rvd vs. autosct in patients with multiple myeloma
-
48:06
the latest insights on immune therapies in myeloma | 2023 imf patient and family seminar
-
3:44
clinical advances with car-ts and bispecifics in r/r myeloma
-
5:40
is myeloma research examining sequencing of car t and bispecifics?